CRIS Current Research Information System

VERUCCHI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.785
AS - Asia 6.855
EU - Europa 6.054
SA - Sud America 465
Continente sconosciuto - Info sul continente non disponibili 415
AF - Africa 400
OC - Oceania 11
Totale 23.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.651
SG - Singapore 1.969
GB - Regno Unito 1.939
VN - Vietnam 1.855
CN - Cina 1.590
IT - Italia 799
DE - Germania 739
SE - Svezia 709
HK - Hong Kong 448
FR - Francia 416
IN - India 363
BR - Brasile 344
RU - Federazione Russa 326
UA - Ucraina 319
IE - Irlanda 220
ZA - Sudafrica 125
NL - Olanda 115
JP - Giappone 110
EE - Estonia 107
CI - Costa d'Avorio 97
FI - Finlandia 97
BD - Bangladesh 94
TG - Togo 85
CA - Canada 67
BG - Bulgaria 58
AR - Argentina 57
KR - Corea 56
PH - Filippine 48
JO - Giordania 47
CH - Svizzera 39
TH - Thailandia 37
ID - Indonesia 32
IQ - Iraq 32
ES - Italia 31
AT - Austria 29
MX - Messico 26
PK - Pakistan 26
SC - Seychelles 26
TW - Taiwan 24
TR - Turchia 23
NG - Nigeria 22
PL - Polonia 21
GR - Grecia 18
BE - Belgio 17
EC - Ecuador 17
UZ - Uzbekistan 16
CL - Cile 11
CO - Colombia 11
IR - Iran 11
LB - Libano 11
MA - Marocco 11
AU - Australia 9
SA - Arabia Saudita 9
VE - Venezuela 9
EG - Egitto 8
IL - Israele 8
LT - Lituania 8
CR - Costa Rica 7
DK - Danimarca 7
JM - Giamaica 7
PE - Perù 7
LU - Lussemburgo 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
ET - Etiopia 5
GT - Guatemala 5
MY - Malesia 5
NI - Nicaragua 5
OM - Oman 5
PS - Palestinian Territory 5
PY - Paraguay 5
AO - Angola 4
CZ - Repubblica Ceca 4
KE - Kenya 4
KZ - Kazakistan 4
NP - Nepal 4
PT - Portogallo 4
A2 - ???statistics.table.value.countryCode.A2??? 3
DZ - Algeria 3
HN - Honduras 3
PA - Panama 3
RS - Serbia 3
SN - Senegal 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
BZ - Belize 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
MD - Moldavia 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
BO - Bolivia 1
Totale 23.551
Salva come PNG Salva come JPEG
Città #
Southend 1.779
Singapore 1.348
Ashburn 1.018
Fairfield 975
Chandler 660
Houston 489
Woodbridge 473
San Jose 460
Seattle 441
Wilmington 429
Hong Kong 423
Ho Chi Minh City 421
Hanoi 366
Santa Clara 361
Cambridge 310
Princeton 309
Ann Arbor 264
Dublin 219
Beijing 214
Dong Ket 213
Council Bluffs 200
Boardman 199
Jacksonville 197
Bologna 177
Lauterbourg 158
Los Angeles 130
Westminster 130
Hefei 126
Nanjing 126
Padova 118
Dallas 109
New York 108
Abidjan 97
Tokyo 97
Berlin 90
Lomé 85
San Diego 80
Helsinki 79
Haiphong 73
Shenyang 69
Buffalo 68
Saint Petersburg 63
Jinan 58
Sofia 57
Da Nang 54
Milan 51
São Paulo 51
Florence 50
Guangzhou 49
Redmond 48
Amman 47
Frankfurt am Main 47
Changsha 45
Nanchang 45
Dearborn 40
Chicago 36
Hebei 36
Des Moines 35
Redondo Beach 33
Tianjin 33
Zhengzhou 33
Turin 32
Mülheim 31
London 30
Medford 30
Shanghai 30
Nuremberg 29
Phoenix 28
Seoul 28
Rome 27
Falls Church 26
Munich 24
Biên Hòa 23
Norwalk 23
Abeokuta 21
Bern 21
Bremen 21
Hải Dương 21
Redwood City 21
The Dalles 20
Falkenstein 19
Hangzhou 19
Jiaxing 19
Mahé 19
Montreal 19
Olalla 19
Amsterdam 17
Atlanta 17
Bühl 17
Ningbo 17
Orem 17
Verona 17
Wuhan 17
Moscow 16
Rio de Janeiro 16
Yubileyny 16
Baghdad 15
Jakarta 15
Toronto 15
Vienna 15
Totale 15.426
Salva come PNG Salva come JPEG
Nome #
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 482
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 394
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 298
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 270
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 266
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 261
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 256
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 253
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 246
A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. 234
Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study 231
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 230
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 223
Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 219
Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study 219
Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy 218
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 218
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 209
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 208
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 206
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 203
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 199
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 199
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 197
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 192
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 192
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 191
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 191
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 187
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 187
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 186
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 185
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 184
Occult HBV infection in PBMCs of HIV+ individuals 182
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 181
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 180
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study 179
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 179
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 178
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 177
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. 177
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 176
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 175
Measles outbreak in the city of Bologna, December 2007 to May 2008 173
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 173
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 173
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 172
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 172
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. 170
Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. 169
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 169
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program 169
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 169
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention. 168
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 168
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. 167
Kidney failure during HIV disease treated with tenofovir, multiple concurrent diseases and drug therapies 166
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 165
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 165
Cmv-specific cell-mediated immunity in immunocompetent adults with primary cmv infection: A case series and review of the literature 164
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 162
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 162
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 160
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients 159
Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals 158
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 158
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 157
105) ANTIVIRAL TREATMENT OF HEPATITIS C IN ITALIAN CHILDREN 156
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. 156
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 155
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 154
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 154
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 151
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 151
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? 151
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 150
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 149
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 148
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 147
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. 146
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 145
Out-of-hospital treatment of hepatitis c increases retention in care among people who inject drugs and homeless persons: An observational study 145
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 142
Hepatitis C Virus (HCV) genotipes in 373 Italian children with HCV infectiona: Changing distribution and correlation with clinical featurees and outcome. 141
Una rara complicanza infettiva in corso di trapianto ortotopico di fegato: gestione della peritonite tubercolare 140
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. 140
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 140
Terapia antiretrovirale con inibitori nucleosidici della trascrittasi inversa ed epatotossicità nei pazienti HIV positivi 139
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 138
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades 136
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 136
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 136
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 136
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 136
Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus 135
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 134
Terapia della infezione da virus C 133
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 132
Totale 18.302
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.096
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.640 0 126 181 250 229 143 91 251 92 280 574 423
2022/20232.676 273 365 147 387 181 206 71 157 475 91 211 112
2023/2024681 60 125 43 54 49 141 40 55 29 34 20 31
2024/20252.844 119 511 236 232 475 150 182 101 28 160 73 577
2025/20267.080 666 481 642 481 816 430 727 379 1.403 523 249 283
2026/2027349 151 198 0 0 0 0 0 0 0 0 0 0
Totale 23.985